TScan Therapeutics Stock (NASDAQ:TCRX)
Previous Close
$1.30
52W Range
$1.02 - $9.69
50D Avg
$1.73
200D Avg
$4.10
Market Cap
$73.57M
Avg Vol (3M)
$419.91K
Beta
1.08
Div Yield
-
TCRX Company Profile
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TCRX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CUE | Cue Biopharma, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| PRQR | ProQR Therapeutics N.V. |
| ARWR | Arrowhead Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| ANNX | Annexon, Inc. |
| CGTX | Cognition Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| ITOS | iTeos Therapeutics, Inc. |
| DRMA | Dermata Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |